We've noticed that you're using an ad blocker

Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.

It's off now Dismiss How do I disable my ad blocker?
❌

How to disable your ad blocker for our site:

Adblock / Adblock Plus
  • Click on the AdBlock / AdBlock Plus icon on the top right of your browser.
  • Click “Don’t run on pages on this domain.” OR “Enabled on this site.”
  • Close this help box and click "It's off now".
Firefox Tracking Prevention
  • If you are Private Browsing in Firefox, "Tracking Protection" may casue the adblock notice to show. It can be temporarily disabled by clicking the "shield" icon in the address bar.
  • Close this help box and click "It's off now".
Ghostery
  • Click the Ghostery icon on your browser.
  • In Ghostery versions < 6.0 click “Whitelist site.” in version 6.0 click “Trust site.”
  • Close this help box and click "It's off now".
uBlock / uBlock Origin
  • Click the uBlock / uBlock Origin icon on your browser.
  • Click the “power” button in the menu that appears to whitelist the current website
  • Close this help box and click "It's off now".
  • ONCOLOGY
  • News
  • Blogs
  • Topics
  • Hematology
  • Image IQ
  • Podcasts
  • Videos
  • Slideshows
  • Conferences

Modern Medicine Network
  • Login
  • Register
Skip to main content
Modern Medicine Network
  • Login
  • Register
Menu
User
Home
  • ONCOLOGY
  • News
  • Blogs
  • Topics
  • Hematology
  • Image IQ
  • Podcasts
  • Videos
  • Slideshows
  • Conferences

SUBSCRIBE: Print / eNewsletter

A Patient Self-Administered Sexual Functioning Questionnaire Is Validated in Prostate Cancer Trials

Jan 1, 1999
Volume: 
8
Issue: 
1
  • Genitourinary Cancers, Prostate Cancer

PHOENIX—A self-administered questionnaire that measures
patients’ sexual problems after radiation therapy for prostate
cancer has now been validated and could provide a means of
standardizing reports of sexual dysfunction after prostate cancer treatment.

“The degree of sexual dysfunction after prostate cancer therapy
varies widely in the literature,” Deborah Watkins Bruner, RN,
said at the American Society of Therapeutic Radiology and Oncology
(ASTRO) annual meeting. “This may be because we are all using
very different scales or ways to measure sexual function.”

When the Radiation Therapy Oncology Group (RTOG) began to examine
available instruments a decade ago, it found that “some were
ridiculously long, with 150 or 200 items on sexual adjustment, and
some were ridiculously expensive,” Ms. Bruner said. RTOG found
the Sexual Adjustment Questionnaire (SAQ), developed by Metcalfe and
Waterhouse in 1986, to be the most “user-friendly,” and
began using it in some of its trials.

Ms. Bruner reported results of a validation study in 471 patients of
a modified 16-item version of the SAQ, measuring five factors: sexual
dysfunction, satisfaction, activity, desire, and fatigue (see table
for sample questions). Patients were given the SAQ pretreatment and
at follow-up.

Sample Questions from the Five-Factor Sexual Adjustment Questionnaire

Dysfunction: When sexually excited, are you able to get an erection?

Satisfaction: Are you satisfied with the frequency of sexual
activity in your life?

Activity: Are you having sexual relations with anyone?

Desire: Do you have a desire for sexual activity?

Fatigue: Are you too tired for sexual activity?

 “The RTOG-modified SAQ proved to be a valid and reliable
measure of sexual function,” Ms. Bruner said. She pointed out
that this patient self-assessment, which asked about degrees of
erectile function (never, sometimes, always), was more reliable than
physician assessment, which asked a yes or no question about erectile
dysfunction, in the same study.

“Physicians are right only about 50% of the time in assessing
erectile function,” she said. “An erection is not an all or
nothing phenomenon, and we are not very good at assessing
patients’ capabilities in areas of quality of life.”

She noted that the modified SAQ will be used in RTOG trials of
prostate cancer, including an upcoming Viagra study. The SAQ is both
sensitive and specific, she said, “meaning that we can delineate
patients on different treatments by their SAQ scores.”

Related Articles

  • Nivolumab/Ipilimumab Combo Approved for Advanced RCC
  • No Improved Outcomes in Prostate Cancer With ADT Plus Mitoxantrone/Prednisone
  • Antibiotics Reduced Efficacy of Checkpoint Inhibitors in RCC, NSCLC
  • Pembrolizumab Offers Better QOL vs Chemo in Advanced Urothelial Cancer
  • First-Line Avelumab/Axitinib Encouraging in Advanced RCC

Resource Topics rightRail

  • Resource Topics
  • Partner Content
Breast Cancer
Lung Cancer
Prostate Cancer
Colorectal Cancer
Melanoma
Cutaneous T-Cell Lymphomas: Mycosis Fungoides and Sézary Syndrome
3 Keys to Success in the Oncology Care Model

Current Issue

Oncology Vol 32 No 4
Apr 15, 2018 Vol 32 No 4
Digital Edition
Subscribe
Connect with Us
  • Twitter
  • Facebook
  • LinkedIn
  • RSS
Modern Medicine Network
  • Home
  • About Us
  • Advertise
  • Advertiser Terms
  • Privacy statement
  • Terms & Conditions
  • Editorial & Advertising Policy
  • Editorial Board
  • Contact Us
Modern Medicine Network
© UBM 2018, All rights reserved.
Reproduction in whole or in part is prohibited.